Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa

Ann Oncol. 2010 May;21(5):1135-7. doi: 10.1093/annonc/mdq044. Epub 2010 Mar 9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Female
  • Heart Neoplasms / drug therapy*
  • Heart Neoplasms / metabolism
  • Heart Neoplasms / secondary
  • Humans
  • Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / secondary
  • Perivascular Epithelioid Cell Neoplasms / drug therapy*
  • Perivascular Epithelioid Cell Neoplasms / metabolism
  • Perivascular Epithelioid Cell Neoplasms / pathology
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Serine-Threonine Kinases / antagonists & inhibitors*
  • Protein-Serine-Threonine Kinases / metabolism
  • Sirolimus / analogs & derivatives*
  • Sirolimus / therapeutic use
  • TOR Serine-Threonine Kinases
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / metabolism
  • Uterine Neoplasms / pathology

Substances

  • Intracellular Signaling Peptides and Proteins
  • Protein Kinase Inhibitors
  • temsirolimus
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Protein-Serine-Threonine Kinases
  • Sirolimus